Pacira Pharms Inc Drug Patent Portfolio
Pacira Pharms Inc owns 4 orange book drugs protected by 30 US patents Given below is the list of Pacira Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11918565 | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions | 02 Feb, 2043 | Active |
| US11931459 | Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions | 17 Mar, 2042 | Active |
| US11033495 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11179336 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11278494 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11304904 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11311486 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11357727 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11426348 | Compositions of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11452691 | Compositions of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11819574 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11819575 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US11925706 | Manufacturing of bupivacaine multivesicular liposomes | 22 Jan, 2041 | Active |
| US8828440 | Corticosteroids for the treatment of joint pain | 04 Aug, 2031 | Active |
| US9555048 | Corticosteroids for the treatment of joint pain | 04 Aug, 2031 | Active |
| US9585838 | Production of multivesicular liposomes | 24 Dec, 2021 | Expired |
| US8182835 | Sustained-release liposomal anesthetic compositions | 18 Sep, 2018 | Expired |
| US8834921 | Sustained-release liposomal anesthetic compositions | 18 Sep, 2018 | Expired |
| US9205052 | Sustained-release liposomal anesthetic compositions | 18 Sep, 2018 | Expired |
| US5891467 | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes | 31 Jan, 2017 | Expired |
| US5962016 | Multivesicular liposomes utilizing neutral lipids to modify in vivo release | 31 Jan, 2017 | Expired |
| US6171613 | Method for producing liposomes with increased percent of compound encapsulated | 01 Oct, 2016 | Expired |
| US5997899 | Method for producing liposomes with increased percent of compound encapsulated | 01 Sep, 2016 | Expired |
| US6193998 | Method for producing liposomes with increased percent of compound encapsulated | 01 Sep, 2016 | Expired |
| US6241999 | Method for producing liposomes with increased percent of compound encapsulated | 01 Sep, 2016 | Expired |
| US5807572 | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride | 15 Sep, 2015 | Expired |
| US5931809 | Epidural administration of therapeutic compounds with sustained rate of release | 14 Jul, 2015 | Expired |
| US5723147 | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride | 03 Mar, 2015 | Expired |
| US6132766 | Multivesicular liposomes with controlled release of encapsulated biologically active substances | 16 Nov, 2013 | Expired |
| US5455044 | Method for treating neurological disorders | 14 May, 2013 | Expired |
Latest Legal Activities on Pacira Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Pacira Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 02 Jul, 2024 | US11819575 |
|
Email Notification
Critical
| 02 Jul, 2024 | US11819575 |
| Mail Patent eCofC Notification | 02 Jul, 2024 | US11819575 |
| Recordation of Patent eCertificate of Correction | 02 Jul, 2024 | US11819575 |
| Post Issue Communication - Certificate of Correction | 14 Jun, 2024 | US11819575 |
|
Email Notification
Critical
| 14 Jun, 2024 | US11819575 |
| Mail Certificate of Correction Memo | 13 Jun, 2024 | US11819575 |
| Certificate of Correction Memo | 11 Jun, 2024 | US11819575 |
|
Electronic Review
Critical
| 07 Jun, 2024 | US11931459 |
| Mail Certificate of Correction Memo | 08 May, 2024 | US11931459 |
| Certificate of Correction Memo | 06 May, 2024 | US11931459 |
|
Email Notification
Critical
| 01 May, 2024 | US11918565 |
|
Email Notification
Critical
| 30 Apr, 2024 | US11918565 |
| Mail Patent eCofC Notification | 30 Apr, 2024 | US11918565 |
| Patent eCofC Notification | 30 Apr, 2024 | US11918565 |
Pacira Pharms Inc's Family Patents
Pacira Pharms Inc drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 35.7% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Pacira Pharms Inc Drug List
Given below is the complete list of Pacira Pharms Inc's drugs and the patents protecting them.
1. Depocyt
Depocyt is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5723147 | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
03 Mar, 2015
(9 years ago)
| Expired |
| US5455044 | Method for treating neurological disorders |
14 May, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Depocyt's drug page
2. Depodur
Depodur is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5891467 | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
31 Jan, 2017
(7 years ago)
| Expired |
| US5962016 | Multivesicular liposomes utilizing neutral lipids to modify in vivo release |
31 Jan, 2017
(7 years ago)
| Expired |
| US6171613 | Method for producing liposomes with increased percent of compound encapsulated |
01 Oct, 2016
(8 years ago)
| Expired |
| US5997899 | Method for producing liposomes with increased percent of compound encapsulated |
01 Sep, 2016
(8 years ago)
| Expired |
| US6193998 | Method for producing liposomes with increased percent of compound encapsulated |
01 Sep, 2016
(8 years ago)
| Expired |
| US6241999 | Method for producing liposomes with increased percent of compound encapsulated |
01 Sep, 2016
(8 years ago)
| Expired |
| US5807572 | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
15 Sep, 2015
(9 years ago)
| Expired |
| US5931809 | Epidural administration of therapeutic compounds with sustained rate of release |
14 Jul, 2015
(9 years ago)
| Expired |
| US5723147 | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
03 Mar, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Depodur's drug page
3. Exparel
Exparel is protected by 18 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11918565 | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
02 Feb, 2043
(18 years from now)
| Active |
| US11931459 | Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions |
17 Mar, 2042
(17 years from now)
| Active |
| US11033495 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11179336 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11278494 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11304904 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11311486 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11357727 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11426348 | Compositions of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11452691 | Compositions of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11819574 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11819575 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US11925706 | Manufacturing of bupivacaine multivesicular liposomes |
22 Jan, 2041
(16 years from now)
| Active |
| US9585838 | Production of multivesicular liposomes |
24 Dec, 2021
(2 years ago)
| Expired |
| US8182835 | Sustained-release liposomal anesthetic compositions |
18 Sep, 2018
(6 years ago)
| Expired |
| US8834921 | Sustained-release liposomal anesthetic compositions |
18 Sep, 2018
(6 years ago)
| Expired |
| US9205052 | Sustained-release liposomal anesthetic compositions |
18 Sep, 2018
(6 years ago)
| Expired |
| US6132766 | Multivesicular liposomes with controlled release of encapsulated biologically active substances |
16 Nov, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exparel's drug page
4. Zilretta
Zilretta is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8828440 | Corticosteroids for the treatment of joint pain |
04 Aug, 2031
(6 years from now)
| Active |
| US9555048 | Corticosteroids for the treatment of joint pain |
04 Aug, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zilretta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List